CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2078
Issued: 2026-10-15

PRODUCT IDENTIFICATION

PRODUCT	KPV 10 mg
SKU / INTERNAL CODE	CRF-2026-2078
PRESENTATION	Lyophilised powder, 10 mg vial
BATCH NUMBER	LOT-2610-2078
CLIENT	veltispeptides.mx
SAMPLE RECEIVED	2026-10-10
ANALYSIS DATE	2026-10-13
PRODUCTION DATE	2026-10-08
ISSUED	2026-10-15
EXPIRY / RETEST	2028-10-15
MOLECULAR FORMULA	C16H30N4O4
MOLECULAR WEIGHT	342.44
CAS NUMBER	N/A

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Agilent 1290 · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C18 4.6×150mm | Temperature: 35°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 1.0 mL/min | Retention time: 4.6 min

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2078
Issued: 2026-10-15

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.6%	PASS
Quantity	95.0-105.0%	10.1 mg (101.0%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	343.4 | Observed: 343.2 | Δ -0.20 Da	PASS
Sequence Coverage (MS/MS)	≥95% | 100% (Lys-Pro-Val, 3 aa)	PASS
Key fragments	b2 244.2 · b3 343.2 · y1 118.1 · y2 219.1	PASS
Modifications	free N-terminal Lys, free C-terminal Val - no blocking groups	PASS

RESEARCH USE ONLY - NOT FOR HUMAN OR VETERINARY USE

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb		<0.05 µg/g	PASS
As		<0.10 µg/g	PASS
Cd		<0.02 µg/g	PASS
Hg		<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.15 EU/mg | PPC recovery 95%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

α-MSH C-terminal tripeptide. Pro2 stabilises against diketopiperazine formation - none detected (<0.1%). Acetate 7.1% w/w.

crafa

CRAFA